Immunology Market (By Drug Class: Monoclonal Antibodies, Fusion Proteins, Immunosuppressants, others; By Disease Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis Of Organ Rejection; By Distribution Channel: Hospital Pharmacie, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Immunology Market 

5.1. COVID-19 Landscape: Immunology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Immunology Market, By Drug Class

8.1. Immunology Market, by Drug Class, 2024-2033

8.1.1 Monoclonal Antibodies

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Fusion Proteins

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Immunosuppressants

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Immunology Market, By Disease Indication

9.1. Immunology Market, by Disease Indication, 2024-2033

9.1.1. Rheumatoid Arthritis

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Psoriatic Arthritis

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Plaque Psoriasis

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Ankylosing Spondylitis

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Inflammatory Bowel Disease

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. Prophylaxis Of Organ Rejection

9.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Immunology Market, By Distribution Channel 

10.1. Immunology Market, by Distribution Channel, 2024-2033

10.1.1. Hospital Pharmacie

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Immunology Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 12. Company Profiles

12.1. AbbVie Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Janssen Global Services, LLC (Johnson & Johnson)

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Novartis AG.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. ALLERGAN.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Amgen Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Other Prominent Players.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Merck Sharp & Dohme Corp.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bristol-Myers Squibb Company

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample